Published in Medical Letter on the CDC and FDA, February 9th, 2003
This recommendation is based on data from the landmark CAPRICORN (CArvedilol Post InfaRction Survival ContRol in Left Ventricular DysfunctioN) trial, which showed that early long-term treatment with Coreg following a heart attack in patients with left ventricular dysfunction could reduce the risk of dying by 23%.
"The CAPRICORN trial is the first major study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.